• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by PolyPid Ltd.

    5/30/25 4:05:39 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PYPD alert in real time by email
    6-K 1 ea0243812-6k_polypid.htm REPORT OF FOREIGN PRIVATE ISSUER

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-16

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the Month of: May 2025 (Report No. 3)

     

    Commission File Number: 001-38428

     

    PolyPid Ltd.

    (Translation of registrant’s name into English)

     

    18 Hasivim Street

    Petach Tikva 495376, Israel

    (Address of principal executive office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

     

    ☒ Form 20-F          ☐ Form 40-F

     

     

     

     

     

    CONTENTS

     

    On May 12, 2025, the Board of Directors of PolyPid Ltd. (the “Company”) approved an increase in the number of ordinary shares, no par value per share, of the Company reserved for issuance under the Company’s Amended and Restated 2012 Share Option Plan (the “Share Option Plan”) by 1,200,000 ordinary shares from 2,312,403 to 3,512,403. A copy of the Share Option Plan, as amended, is filed with this report as Exhibit 99.1.

     

    This Report of Foreign Private Issuer on Form 6-K, including its exhibit, is incorporated by reference into the Registrant’s registration statements on Form F-3 (File No. 333-276826, File No. 333-280658, File No. 333-281863, and File No. 333-284376) and Form S-8 (File No. 333-239517, File No. 333-271060, File No. 333-277703 and File No. 333-280662) filed with the Securities and Exchange Commission to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished. 

     

    1

     

    EXHIBIT INDEX

     

    Exhibit No.    
    99.1   Amended and Restated 2012 Share Option Plan.

     

    2

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

      POLYPID LTD.
         
    Date: May 30, 2025 By: /s/ Dikla Czaczkes Akselbrad
        Name:  Dikla Czaczkes Akselbrad
        Title: Chief Executive Officer

     

    3

     

    Get the next $PYPD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PYPD

    DatePrice TargetRatingAnalyst
    6/5/2025$9.00Buy
    Roth Capital
    6/2/2025$11.00Buy
    H.C. Wainwright
    1/28/2025$13.00Buy
    Rodman & Renshaw
    2/11/2022$23.00 → $17.00Strong Buy
    Raymond James
    9/14/2021$14.00Market Outperform
    JMP Securities
    7/30/2021$24.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $PYPD
    SEC Filings

    View All

    SEC Form 6-K filed by PolyPid Ltd.

    6-K - PolyPid Ltd. (0001611842) (Filer)

    2/4/26 4:05:01 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by PolyPid Ltd.

    SCHEDULE 13G/A - PolyPid Ltd. (0001611842) (Subject)

    1/30/26 1:02:52 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by PolyPid Ltd.

    6-K - PolyPid Ltd. (0001611842) (Filer)

    12/31/25 4:01:17 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

    PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question

    1/28/26 8:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

    PETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. "Brooke's appointment marks an exciting and pivotal moment for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Her global expertise in the surgical market, specifically in infection prevention and advanced surgical solutions, combined with her extensive experience leading corporate strategy and corporate development transactions, will be instrumental in transfor

    12/16/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Announces Positive FDA Pre-NDA Meeting Minutes for D-PLEX₁₀₀ Supporting NDA Submission

    PETACH TIKVA, Israel, Dec. 03, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a formal pre-New Drug Application ("NDA") meeting minutes from the U.S. Food and Drug Administration ("FDA") supporting the NDA submission of D-PLEX100, the Company's lead product candidate for the prevention of surgical site infections in abdominal colorectal surgeries. The FDA agreed that the Company's existing clinical data package, including results from the Phase 3 SHIELD II trial, appears adequate to support NDA submission and review. The FDA also agreed to a rolling N

    12/3/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Roth Capital initiated coverage on PolyPid Ltd. with a new price target

    Roth Capital initiated coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $9.00

    6/5/25 7:35:43 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on PolyPid Ltd. with a new price target

    H.C. Wainwright resumed coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $11.00

    6/2/25 8:53:56 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on PolyPid Ltd. with a new price target

    Rodman & Renshaw initiated coverage of PolyPid Ltd. with a rating of Buy and set a new price target of $13.00

    1/28/25 7:16:12 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Financials

    Live finance-specific insights

    View All

    PolyPid to Report Fourth Quarter 2025 Financial Results and Operational Highlights on February 11, 2026

    PETACH TIKVA, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 11, 2026. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question

    1/28/26 8:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Provides Corporate Update and Reports Third Quarter 2025 Financial Results

    Face-to-Face Pre-NDA Meeting with the FDA Scheduled for Early December; NDA Submission for D-PLEX₁₀₀ On Track for Early 2026 Advancements in Discussions with Potential U.S. Partners Following Positive Phase 3 Trial Results Company Continues to Advance Towards Commercial Manufacturing Readiness with Successful Completion of IMOH GMP Inspection Conference Call Scheduled for Today at 8:30 AM ET PETACH TIKVA, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today provided a corporate update and reported financial results for the three and nine months ended September 30, 202

    11/12/25 7:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid to Report Third Quarter 2025 Financial Results and Operational Highlights on November 12, 2025

    PETACH TIKVA, Israel, Oct. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2025 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations. To ensure you are connected prior to the beginning of the call, PolyPid suggests registering a minimum of 5 minutes before the start of the call. For those not planning to ask a question o

    10/29/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Leadership Updates

    Live Leadership Updates

    View All

    PolyPid Appoints Veteran MedTech Leader Brooke Story as Chairman of the Board of Directors

    PETACH TIKVA, Israel, Dec. 16, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Brooke Story as Chairman of the Board of Directors, effective as of December 11, 2025. "Brooke's appointment marks an exciting and pivotal moment for PolyPid," said Dikla Czaczkes Akselbrad, Chief Executive Officer of PolyPid. "Her global expertise in the surgical market, specifically in infection prevention and advanced surgical solutions, combined with her extensive experience leading corporate strategy and corporate development transactions, will be instrumental in transfor

    12/16/25 8:30:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Appoints Dr. Nurit Tweezer-Zaks as Chief Medical Officer

    PETACH TIKVA, Israel, Aug. 12, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Dr. Nurit Tweezer-Zaks, M.D., M.B.A., as Chief Medical Officer, effective as of August 18, 2025. Dr. Tweezer-Zaks, who has served on PolyPid's Board of Directors (the "Board") since November 2023, will step down from the Board, effective as of August 17, 2025 as she assumes this new executive role. "We are delighted to welcome Dr. Tweezer-Zaks to the executive team at this pivotal time for PolyPid following our positive Phase 3 SHIELD II trial results," said Dikla Czaczkes Aks

    8/12/25 8:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors

    PETACH TIKVA, Israel, Nov. 07, 2023 (GLOBE NEWSWIRE) -- PolyPid Ltd. (NASDAQ:PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced the appointment of Nurit Tweezer-Zaks, M.D., M.B.A, to its Board of Directors, effective November 6, 2023, following the retirement of Anat Tsour Segal. Dr. Tweezer-Zaks is a biopharmaceutical industry veteran with extensive executive business development, clinical, and R&D expertise. She is an experienced sector investor and was a practicing physician for nearly 15 years. "We are thrilled to welcome Dr. Tweezer-Zaks to the PolyPid Board. She has had a distinguished career as a practicing physic

    11/7/23 7:00:00 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $PYPD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    12/12/24 7:05:07 AM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    11/29/24 1:20:33 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by PolyPid Ltd.

    SC 13G/A - PolyPid Ltd. (0001611842) (Subject)

    10/28/24 4:01:03 PM ET
    $PYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care